Veracyte Announces Release of Inaugural ESG Report
BIOMARKER
1. Veracyte, Inc. has announced the release of its inaugural Environmental, Social and Governance (ESG) Report for 2023.
2. This report sets the foundation for Veracyte's ESG performance and outlines future ambitions.
3. CEO Marc Stapley emphasized Veracyte's responsibility to advance its ESG efforts, benefiting patients, shareholders, employees, and other stakeholders.
4. The 2023 ESG Report includes establishing an executive-level ESG Steering Committee and Board-level oversight of ESG matters.
5. The company also highlighted its diverse workforce with 59% women, and 60% of its executive leadership team being female.
6. Veracyte's governance practices are being enhanced by proposing a transition to a declassified Board of Directors at the 2023 annual meeting.
7. They are pursuing BREEAM certification for a new facility under construction in Marseille, France.
8. Disclosures in the report were informed by established frameworks such as the Sustainability Accounting Standards Board (SASB) standards.
9. Veracyte is a global diagnostics company aiming to transform cancer care with high-performing tests for diagnostic, prognostic, and treatment decisions.
10. The forward-looking statements in the report include Veracyte's plans and expectations related to ESG-related topics and the potential impact on the environment and stakeholders.